Argenx
ARGX
#495
Rank
โ‚น4.865 T
Marketcap
โ‚น77,859
Share price
0.81%
Change (1 day)
57.28%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2026 (TTM): โ‚น418.32 Billion

According to Argenx 's latest financial reports the company's current revenue (TTM ) is โ‚น451.21 Billion. In 2025 the company made a revenue of โ‚น372.79 Billion an increase over the revenue in the year 2024 that were of โ‚น187.87 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น418.32 B12.21%
2025 โ‚น372.79 B98.43%
2024 โ‚น187.87 B84.03%
2023 โ‚น102.08 B200.36%
2022 โ‚น33.98 B
2019 โ‚น6.24 B206.69%
2018 โ‚น2.03 B-36.49%
2017 โ‚น3.20 B175.95%
2016 โ‚น1.16 B111.53%
2015 โ‚น0.54 B50.13%
2014 โ‚น0.36 B19.39%
2013 โ‚น0.30 B